Treatment Sequencing in Recurrent Low-Grade Serous Ovarian Cancer: A Case-Based Expert Discussion

This case-based program explores real-world treatment selection and sequencing for recurrent low-grade serous ovarian cancer. Expert faculty will examine targeted and hormonal therapy options, patient-specific considerations, and practical strategies for managing treatment-related adverse events.

Learning Objectives

Apply evidence-based strategies for treatment sequencing in low-grade serous ovarian cancer

Evaluate targeted therapy options, including MEK and FAK inhibition approaches

Manage common and clinically significant adverse events associated with therapy

Incorporating patient-specific factors into treatment decision-making

Supported in part by Verastem

Faculty:

Rachel N. Grisham, MD
Section Head, Ovarian Cancer
Director, Gynecologic Medical Oncology, MSK Westchester
Memorial Sloan Kettering Cancer Center
USA

Premal H. Thaker, M.D.

David & Lynn Mutch Distinguished Professor of Obstetrics & Gynecology
Chief of Gynecologic Oncology
Director of Gynecologic Oncology Clinical Research
Professor in Gynecologic Oncology
Washington University School of Medicine
USA

Courtney Arn, APRN-CNP

Nurse Practitioner
The Ohio State University Wexner Medical Center
James Comprehensive Cancer Center
USA

Miranda Benfield, PharmD, BCOP

Oncology Clinical Pharmacy Specialist - Gynecology Oncology
Department of Pharmacy
Levine Cancer Institute, Atrium Health 
USA

Wendel Naumann, MD
Director of Minimally Invasive Surgery in Gynecologic Oncology
Carolinas Medical Center
Associate Medical Director of Clinical Trials
Levine Cancer Institute, Atrium Health
USA

Supported in part by

Summary

Availability:

On-Demand

Cost:

FREE

Create Account